Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Carnosine · Peripheral Arterial Disease Patients Enrollment reduced: 144 → 120 participants Shahid BabaPhase 1/2 NCT06480760
  2. Minor: TOS-358 · HR+ HER2- Breast Cancer Trial sites expanded: 18 → 25 locations Totus MedicinesPhase 1 NCT05683418
  3. Minor: Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry Trial sites expanded: 318 → 324 locations Genzyme, a Sanofi CompanyNot specified NCT00358943
  4. Minor: Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Enrollment increased: 9 → 10 participants Ruijin HospitalPhase 1 NCT07885306
  5. Minor: Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain Trial sites expanded: 1 → 5 locations Novartis PharmaceuticalsNot specified NCT07598448
  6. Minor: How Elinzanetant is Used and How Well it Works · Menopause Symptoms Trial sites expanded: 0 → 22 locations BayerNot specified NCT07490431
  7. Minor: Fabry Disease Registry & Pregnancy Sub-registry Trial sites expanded: 284 → 289 locations Genzyme, a Sanofi CompanyNot specified NCT00196742
  8. Minor: MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study Trial sites expanded: 2393 → 2449 locations Stryker InstrumentsNot specified NCT03072927
  9. Minor: NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage Enrollment increased: 280 → 384 participants Southwest Hospital, ChinaNot applicable NCT06894433
  10. Minor: Molecular and Imaging Studies of Cardiovascular Health and Disease Enrollment increased: 5000 → 6000 participants National Heart Centre SingaporeNot specified NCT02804269
  11. Minor: Apalutamide (ARN-509) · Non-Metastatic Castration-Resistant Prostate Cancer Study completion pushed from Dec 31, 2027 to Dec 31, 2029 Aragon Pharmaceuticals, Inc.Phase 3 NCT01946204
  12. Minor: Subcutaneous Nomlabofusp · Friedreich's Ataxia Start date changed from estimate of Oct 26, 2026 to Aug 5, 2026 Larimar Therapeutics, Inc.Phase 3 NCT07778836
  13. Minor: Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy Start date pushed from Nov 9, 2026 to Nov 30, 2026 Grünenthal GmbHPhase 2 NCT07911995
  14. Minor: Erdafitinib (JNJ-42756493) · Urothelial Cancer Study completion pushed from Mar 31, 2027 to Dec 31, 2027 Janssen Research & Development, LLCPhase 2 NCT02365597
  15. Minor: VG2025 Intravenous Injection · Advanced Solid Tumors Start date changed from estimate of Sep 4, 2026 to Nov 11, 2026 Virogin Biotech Ltd.Phase 1/2 NCT07682870
  16. Minor: ALKS 7290 as an Adjunctive Therapy to Antidepressants · Major Depressive Disorder Start date changed from estimate of Oct 2026 to Nov 9, 2026 Alkermes, Inc.Phase 2 NCT07901179
  17. Minor: Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy · Active Crohn's Disease Trial sites expanded: 4 → 7 locations James LewisNot applicable NCT07356232
  18. Minor: TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Study completion pushed from Sep 2026 to Nov 2026 Tango Therapeutics, Inc.Phase 1/2 NCT05887492
  19. Minor: Niraparib Combination Therapies · Metastatic Castration-Resistant Prostate Cancer Study completion pushed from Dec 31, 2026 to Dec 31, 2027 Janssen Research & Development, LLCPhase 2 NCT03431350
  20. Minor: RGX-314 Gene Therapy Administered in the Suprachoroidal Space · Neovascular Age-Related Macular Degeneration (nAMD) Primary completion date changed from estimate of Aug 2026 to Oct 13, 2026 AbbViePhase 2 NCT04514653
  21. Minor: Antibiotic Treatment Strategies · Pneumonia in Outpatient Settings: (STAMPP) Trial sites expanded: 4 → 9 locations Ann & Robert H Lurie Children's Hospital of ChicagoNot applicable NCT06986148
  22. Minor: LB-LR1109, Administered Alone · Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC Study completion pushed from Mar 2028 to Dec 2028 LG ChemPhase 1 NCT06332755
  23. Minor: Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma Trial arms changed: 5 → 8 Janssen Research & Development, LLCPhase 1 NCT06768489
  24. Minor: AWT020 · Advanced Solid Tumors Start date changed from estimate of Sep 11, 2026 to Oct 15, 2026 Anwita BiosciencesPhase 1 NCT07822919
  25. Minor: Impact of a Painkiller Product on Quality-of-Life and Daily Functioning Start date pushed from Nov 2026 to Dec 2026 HALEONNot specified NCT07909590